FDA Approves ENTYVIO — Takeda Pharmaceuticals America, Inc.

# FDA Approves Takeda's ENTYVIO for Inflammatory Bowel Disease Takeda Pharmaceuticals America, Inc. received FDA approval for ENTYVIO (vedolizumab), an intravenous integrin receptor antagonist for inflammatory bowel disease, positioning the company to capture market share in the competitive IBD treatment segment. The approval of this novel mechanism-of-action therapy is expected to strengthen Takeda's gastroenterology portfolio and drive revenue growth in a market valued at billions of dollars annually.